Status:
COMPLETED
A Registry for Patients Taking Uptravi
Lead Sponsor:
Actelion
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18-99 years
Brief Summary
This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of...
Eligibility Criteria
Inclusion
- Signed patient informed consent form (ICF).
- Patients ≥ 18 years of age at time of Uptravi initiation, and
- Patients who initiate Uptravi:
- at enrollment, or
- less than or equal to 60 days prior to enrollment and have a documented titration regimen (defined as all documented dose changes including, but not limited to: starting dose and dates and highest tolerated dose and dates)
Exclusion
- Patients previously exposed to Uptravi treatment during a clinical trial.
- Patients that previously discontinued Uptravi for any reason, prior to study enrollment (discontinuation defined as an interruption of therapy greater than or equal to 30 days).
- Patients enrolled in a blinded clinical trial or in a clinical trial involving an unapproved drug.
Key Trial Info
Start Date :
November 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 21 2021
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT03278002
Start Date
November 1 2016
End Date
September 21 2021
Last Update
March 30 2025
Active Locations (85)
Enter a location and click search to find clinical trials sorted by distance.
1
University of South Alabama
Mobile, Alabama, United States, 36617
2
Pulmonary Associates
Phoenix, Arizona, United States, 85006
3
Cardioivascular Consultants, Ltd.
Phoenix, Arizona, United States, 85027
4
University of Arizona-Clinical Translational and Regenerative Medicine
Tucson, Arizona, United States, 85724